Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents (Grand-DES)

April 22, 2026 updated by: Hyo-Soo Kim, Seoul National University Hospital

The objective of this study is to evaluate the long-term efficacy and safety of coronary stenting with the various types of drug-eluting stents (DES) and to determine clinical device and procedural success during commercial use of DES in the real world.

The investigators will compare EES (Xience V/Promus and Xience Prime), SES (Cypher), ZES (Resolute Integrity, Endeavor Resolute, Endeavor), and BES (Biomatrix, Biomatrix Flex, and Nobori).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The Grand Drug-Eluting Stent (Grand-DES) Registry incorporated five different multicenter registries in South Korea. The EXCELLENT prospective cohort and the EXCELLENT-PRIME registry were dedicated for durable polymer-coated everolimus-eluting stents (DP-EES; Xience V/Promus and Xience Prime) or 1st-generation sirolimus-eluting stents (Cypher), the HOST-RESOLINTE and RESOLUTE-Korea registry for durable polymer-coated zotarolimus-eluting stents (DP-ZES; Resolute Integrity and Endeavor Resolute) or 1st-generation Endeavor-ZES, and the HOST-BIOLIMUS-3000-Korea registry for biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, and Nobori). During the period of 2008 through 2014, all registries enrolled all-comers without any exclusion criteria except patient's withdrawal of consent.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
17286

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • South Korea
      • Anyang, South Korea
        • Hallym University Sacred Heart Hospital
      • Busan, South Korea
        • Kosin University Gospel Hospital
      • Cheonan, South Korea
        • Soon Chun Hyang University Hospital Cheonan
      • Cheonan, South Korea
        • Dankook University Hospital
      • Daejeon, South Korea
        • Chungnam National University Hospital
      • Gwangju, South Korea
        • Chonnam National University Hospital
      • Gwangju, South Korea
        • Gwangju Christian Hospital
      • Gwangju, South Korea
        • Kwangju Veterans Hospital
      • Iksan, South Korea
        • Wonkwang University Hospital
      • Iksan, South Korea
        • Chonbuk National University Hospital
      • Ilsan, South Korea
        • Inje University Ilsan Paik Hospital
      • Ilsan, South Korea
        • National Health Insurance Corporation Ilsan Hospital
      • Inchon, South Korea
        • Inha University Hospital
      • Jeonju, South Korea
        • Presbyterian Medical Center
      • Jeonju, South Korea
        • Chungbuk National University Hospital
      • Jinju, South Korea
        • Gyeongsang National University Hospital
      • Pusan, South Korea
        • Inje University Pusan Paik Hospital
      • Pusan, South Korea
        • Pusan National University Hospital
      • Seongnam, South Korea
        • Seoul National University Bundang Hospital
      • Seongnam, South Korea
        • Bundang CHA Medical Center
      • Seoul, South Korea
        • Korea University Guro Hospital
      • Seoul, South Korea
        • Samsung Medical Center
      • Seoul, South Korea
        • Gangnam Severance Hospital
      • Seoul, South Korea
        • Kyung Hee University Medical Center
      • Seoul, South Korea
        • Hanyang University Medical Center
      • Seoul, South Korea
        • Seoul Boramae Hospital
      • Seoul, South Korea
        • Kyung Hee University Hospital at Gangdong
      • Seoul, South Korea
        • Yonsei University Medical Center
      • Seoul, South Korea
        • Soonchunhyang University Hospital
      • Seoul, South Korea
        • Ewha Womans University Medical Center Mokdong Hospital
      • Seoul, South Korea
        • Gangbuk Samsung Hospital
      • Seoul, South Korea
        • Hallym University Kangdong Sacred Heart Hospital
      • Suncheon, South Korea
        • St. Carollo Hospital
      • Uijeongbu-si, South Korea
        • Uijeongbu St. Mary's Hospital
    • Gangwon-do
      • Wŏnju, Gangwon-do, South Korea
        • Wonju Severance Christian Hospital
    • Gyeonggi-do
      • Bucheon-si, Gyeonggi-do, South Korea
        • Sejong General Hospital
    • Jongno-gu
      • Seoul, Jongno-gu, South Korea, 03080
        • Seoul National University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

A total of 17,286 patients derived from a population of patients receiving percutaneous coronary intervention for ischemic heart disease will be enrolled in the present registry.

Description

Inclusion Criteria:

  • The patient agrees to participate in this study by signing the informed consent form.
  • Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.

Exclusion Criteria:

  • There are no exclusion criteria for this registry.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
HOST-BIOLIMUS-Korea-3000
Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
Device: Biomatrix; Biomatrix Flex; Nobori
Biodegradable polymer-coated biolimus-eluting stents
Other Names:
  • BP-BES
EXCELLENT-PRIME
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
Device: Xience Prime
Durable polymer-coated everolimus-eluting stents
Other Names:
  • DP-EES-Prime
EXCELLENT Prospective cohort
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
Device: Xience V/Promus; Cypher
Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
Other Names:
  • DP-EES; SES
HOST-RESOLINTE
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
Device: DP-ZES-RI
Durable polymer-coated zotarolimus-eluting stents
Other Names:
  • Resolute Integrity
RESOLUTE-Korea
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
Device: Endeavor; Resolute
Durable polymer-coated zotarolimus-eluting stents
Other Names:
  • DP-ZES

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Target lesion failure
Time Frame: 36 months
A composite of cardiac death, target-vessel myocardial infarction, and clinically-driven target lesion revascularization
36 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Patient-oriented composite outcome
Time Frame: 36 months
A composite of all-cause death, all-cause myocardial infarction, and any repeat revascularization
36 months
All-cause death
Time Frame: 36 months
All-cause death
36 months
Cardiac death
Time Frame: 36 months
Cardiac death
36 months
All-cause myocardial infarction
Time Frame: 36 months
All-cause myocardial infarction
36 months
Target-vessel myocardial infarction
Time Frame: 36 months
Target-vessel myocardial infarction
36 months
Any repeat revascularization
Time Frame: 36 months
Any repeat revascularization
36 months
Clinically-driven target vessel revascularization
Time Frame: 36 months
Clinically-driven target vessel revascularization
36 months
Clinically-driven target lesion revascularization
Time Frame: 36 months
Clinically-driven target lesion revascularization
36 months
Definite or probable stent thrombosis
Time Frame: 36 months
Definite or probable stent thrombosis
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Seoul National University Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Hyo-Soo Kim, MD, PhD, Seoul National University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2008

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 30, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 15, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 15, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 24, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 27, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 22, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Grand-DES

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Biomatrix; Biomatrix Flex; Nobori

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings